PMID- 24121312 OWN - NLM STAT- MEDLINE DCOM- 20140625 LR - 20161125 IS - 1473-5628 (Electronic) IS - 0143-3636 (Linking) VI - 35 IP - 1 DP - 2014 Jan TI - Correlation of (18)F-fluoromisonidazole PET findings with HIF-1alpha and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. PG - 30-5 LID - 10.1097/MNM.0000000000000010 [doi] AB - OBJECTIVE: We evaluated tumor hypoxia using F-fluoromisonidazole (F-FMISO) PET in relation to the expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and p53 in patients with head and neck cancer and compared the results with those obtained using 2-deoxy-2-F-fluoro-D-glucose (F-FDG) PET. MATERIALS AND METHODS: A total of 28 tumors (23 primary tumors and five metastatic lymph nodes) from 24 patients with newly diagnosed head and neck cancer were examined with F-FMISO PET and F-FDG PET. The F-FMISO PET images were scaled to the venous blood concentration of F-FMISO activity to produce tumor-to-blood (T/B) values. Hypoxia was defined as a region with a T/B ratio greater than or equal to 1.2. The maximum T/B (T/Bmax) and hypoxic volumes were calculated by region-of-interest analysis. For F-FDG PET, the maximum standardized uptake value (SUVmax) and hypermetabolic volume were calculated by region-of-interest analysis. The expressions of HIF-1alpha and p53 using immunohistochemistry were estimated in tumor tissue samples. RESULTS: A weak correlation was observed between hypoxic volume and T/Bmax (r=0.53, P=0.003) on using F-FMISO PET and between hypermetabolic volume and SUVmax (r=0.38, P=0.046) on using F-FDG PET. The hypoxic volume using F-FMISO PET and hypermetabolic volume using F-FDG PET also showed a weak correlation (r=0.44, P=0.020). The values of F-FMISO hypoxic volume showed a weak correlation with HIF-1alpha (r=0.40, P=0.037) and p53 (r=0.47, P=0.012) obtained on immunohistochemical examination. CONCLUSION: This study demonstrates a weak correlation between hypoxic volume measured by F-FMISO PET and expressions of HIF-1alpha and p53 in head and neck cancer. FAU - Norikane, Takashi AU - Norikane T AD - Departments of aRadiology bMedical Physics cDiagnostic Pathology dOral and Maxillofacial Surgery eOtolaryngology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Yamamoto, Yuka AU - Yamamoto Y FAU - Maeda, Yukito AU - Maeda Y FAU - Kudomi, Nobuyuki AU - Kudomi N FAU - Matsunaga, Toru AU - Matsunaga T FAU - Haba, Reiji AU - Haba R FAU - Iwasaki, Akinori AU - Iwasaki A FAU - Hoshikawa, Hiroshi AU - Hoshikawa H FAU - Nishiyama, Yoshihiro AU - Nishiyama Y LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Nucl Med Commun JT - Nuclear medicine communications JID - 8201017 RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Tumor Suppressor Protein p53) RN - 082285VIDF (fluoromisonidazole) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 8FE7LTN8XE (Misonidazole) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biological Transport MH - Female MH - *Fluorodeoxyglucose F18/metabolism MH - *Gene Expression Regulation, Neoplastic MH - Head and Neck Neoplasms/*diagnostic imaging/metabolism MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism MH - Male MH - Middle Aged MH - Misonidazole/*analogs & derivatives/metabolism MH - *Positron-Emission Tomography MH - Tumor Suppressor Protein p53/*metabolism EDAT- 2013/10/15 06:00 MHDA- 2014/06/26 06:00 CRDT- 2013/10/15 06:00 PHST- 2013/10/15 06:00 [entrez] PHST- 2013/10/15 06:00 [pubmed] PHST- 2014/06/26 06:00 [medline] AID - 10.1097/MNM.0000000000000010 [doi] PST - ppublish SO - Nucl Med Commun. 2014 Jan;35(1):30-5. doi: 10.1097/MNM.0000000000000010.